Phase 1 Start~month

Phase 1 Start: A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerabi

Indication
Healthy Participants

Other upcoming events for AZN

Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety
Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
Phase 1 StartPhase 1 Start: A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME)
Phase 2 StartPhase 2 Start: A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Sa
Phase 3 ReadoutPhase 3 Topline: A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 1 Start: A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerabi — AZN Phase 1 Start | BioSniper